Our Services
Medical Information
Helpful Resources
Published on: 1/31/2026
Farxiga (dapagliflozin) 10 mg is an SGLT2 inhibitor taken once daily to manage type 2 diabetes, reduce heart failure hospitalizations, and protect kidney function in chronic kidney disease—even in people without diabetes. Common side effects include increased urination, thirst, and mild dizziness. Seek urgent care for symptoms of ketoacidosis (nausea, vomiting, belly pain, fast breathing), serious urinary or genital infection, allergic reaction, little or no urination, or fainting. Sick-day rules and who should avoid Farxiga matter for safe use.
Because symptoms like dizziness, excess thirst, or nausea can signal either expected side effects or a serious complication, it's important to know which category yours fall into before deciding whether to wait, call your doctor, or seek emergency care. Take a free, instant, online symptom check to clarify what your symptoms may mean and get personalized guidance on next steps.
Reviewed for medical accuracy: 07/09/2026
Not seeing your question? No worries.
Submit your own QuestionFarxiga (generic name: dapagliflozin) is a prescription medication that has become an important part of care for several long-term health conditions. If you or a loved one has been prescribed Farxiga 10 mg, it's normal to want clear, practical information about what it does, how it works, and what to watch for. This guide is based on well-established medical guidance and is written in everyday language to help you feel informed—not overwhelmed.
Farxiga belongs to a class of medicines called SGLT2 inhibitors. These medications help the kidneys remove excess sugar and sodium from the body through urine. By doing this, Farxiga can improve blood sugar control and support heart and kidney health.
Farxiga is taken once daily by mouth, usually in the morning, with or without food. The 10 mg dose is the most common maintenance dose for most approved uses.
Farxiga is approved for several important medical conditions. Your doctor may prescribe it for one or more of the following:
Farxiga helps lower blood sugar levels in adults with type 2 diabetes, especially when diet and exercise alone are not enough.
Farxiga is not used for type 1 diabetes or diabetic ketoacidosis.
Farxiga is approved to reduce the risk of hospitalization and death in adults with certain types of heart failure—even in people without diabetes.
Farxiga can slow the progression of kidney disease and reduce the risk of kidney failure in some adults.
Normally, your kidneys filter sugar out of the blood and then reabsorb it. Farxiga blocks that reabsorption, allowing extra sugar to leave the body through urine.
This leads to:
Because it increases urination, staying well hydrated is important.
Many people tolerate Farxiga well, but your body may need some time to adjust.
These effects often settle as your body adapts. Your doctor may monitor kidney function and blood pressure, especially early on.
These are usually manageable and not dangerous, but still worth mentioning to your doctor:
Because Farxiga causes fluid loss, it's important to recognize the warning signs early—if you're experiencing symptoms like unusual fatigue, dizziness, or dark urine, try Ubie's free AI-powered Dehydration symptom checker to better understand what your body might be telling you.
These are rare, but important to recognize:
These situations require immediate medical attention.
You should speak to a doctor immediately or seek urgent care if you notice:
These symptoms could indicate a life-threatening or serious condition, and should never be ignored.
Farxiga may not be right for everyone. Tell your doctor if you have:
Your doctor will weigh the benefits and risks carefully.
To get the most benefit while reducing risks:
If you become sick, stop eating, or are dehydrated due to vomiting or diarrhea, contact your healthcare provider. Temporary medication adjustments may be needed.
Some people lose a small amount of weight, mainly due to fluid and sugar loss. It is not a weight-loss drug.
No. Farxiga may be used alongside insulin or other medications, but it does not replace them unless your doctor specifically changes your treatment plan.
Blood sugar effects may begin within days, but heart and kidney benefits are seen over months.
Farxiga 10 mg is a well-studied medication with proven benefits for type 2 diabetes, heart failure, and chronic kidney disease. For many people, it improves quality of life and long-term health outcomes when taken as directed.
That said, no medication is risk-free. Paying attention to hydration, early symptoms, and regular check-ins with your healthcare provider makes a real difference.
If anything feels unusual, severe, or concerning—or if you think a symptom could be life threatening—speak to a doctor right away. Your health and safety always come first.
(References)
* Scott LJ. Dapagliflozin: A Review in Type 2 Diabetes, Heart Failure with Reduced Ejection Fraction and Chronic Kidney Disease. Drugs. 2021 Jul;81(10):1199-1210. doi: 10.1007/s40265-021-01540-3. PMID: 34185123.
* McMurray JJV, Solomon SD, Inzucchi SC, Køber L, Kosiborod MN, Martinez JND, O'Meara MF, Rodgaard J, Sha K, Choudhry NK, Cunningham J, Ejvinsson D, Häggström E, Lam CSP, Goh TH, Petersson M, Wessman P, Langkilde AM; DAPA-HF Trial Committee and Investigators. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019 Nov 21;381(21):1995-2008. doi: 10.1056/NEJMoa1911303. Epub 2019 Sep 15. PMID: 31532729.
* Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene TM, Hou FF, Mann JFE, McMurray JJV, Wright EM, Wong MG, Rossing P, Sjöström CD, Toto H, Langkilde AM, Wheeler DC; DAPA-CKD Trial Committees and Investigators. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020 Oct 8;383(15):1436-1446. doi: 10.1056/NEJMoa2024816. Epub 2020 Sep 24. PMID: 32970396.
* Wiviott SD, Raz I, Bonaca MS, Mosenzon O, Kato ET, Cahn AV, Silverman DA, Zelniker CE, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Thuren T, Cordero-Monte M, Hirshberg B, Frederich R, Dahmen M, Salsali A, Scirica BM, Braunwald E; DECLARE–TIMI 58 Investigators. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019 Jan 24;380(4):347-357. doi: 10.1056/NEJMoa1812389. Epub 2018 Nov 10. PMID: 30415602.
* Li J, Zhang D, Zhao H, Li H, Chen W. Safety and Tolerability of Dapagliflozin: A Systematic Review and Meta-Analysis of Clinical Trials. Cardiovasc Diabetol. 2021 Mar 18;20(1):64. doi: 10.1186/s12933-021-01258-3. PMID: 33736569; PMCID: PMC7974441.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.